Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER vs PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Replacement of extracellular fluid and electrolytes; provides buffering capacity via bicarbonate precursor (acetate) and maintains physiological p H.
The drug is a bicarbonate-based peritoneal dialysis solution that buffers metabolic acidosis, removes uremic toxins, and corrects electrolyte imbalances via diffusion and ultrafiltration across the peritoneal membrane. It does not have a traditional receptor-mediated mechanism.
Intravenous replacement of intravascular volume and electrolytes in patients with normal or slightly acidic p H,Maintenance of fluid and electrolyte balance during surgery or in critical care,Correction of hypovolemia when isotonic fluid administration is appropriate
FDA-approved for continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD) in patients with end-stage renal disease (ESRD),Off-label uses include acute kidney injury (AKI) requiring dialysis in select settings
Intravenous infusion, rate adjusted based on clinical status and electrolyte needs; typical adult dose is 500-1000 m L over 1-2 hours.
Intravenous infusion only. Each 1000 m L bag contains 4 g of amino acids and 2.5 g of lipids. Typical adult dose: 1.5-2.0 g/kg/day of amino acids (equivalent to 37.5-50 m L/kg/day) and 1.0-1.5 g/kg/day of lipids. Administer at a rate not to exceed 0.11 g/kg/hour of amino acids and 0.15 g/kg/hour of lipids. For a 70 kg patient, this equals approximately 2.6-3.5 L/day.
Not applicable; components follow first-order kinetics with rapid redistribution. Lactate half-life ~15-30 minutes (hepatic metabolism).
Calcium: terminal half-life 4-6 hours in patients with normal renal function; magnesium: terminal half-life 3-5 hours. Prolonged in renal impairment.
Acetate is metabolized primarily in the liver and muscles to bicarbonate.
The solution components (bicarbonate, lactate, dextrose, electrolytes) are not metabolized by the liver; bicarbonate and lactate are buffer precursors converted via endogenous pathways; dextrose is absorbed and metabolized systemically; electrolytes are regulated by renal and non-renal mechanisms.
Primarily renal; >95% of infused ions (sodium, chloride, lactate, calcium, magnesium) are excreted unchanged in urine. Biliary/fecal elimination negligible (<1%).
Primarily renal excretion; ~70% of calcium dose and ~60% of magnesium dose excreted unchanged in urine. Fecal elimination accounts for ~20% and ~30%, respectively. Biliary excretion is minimal.
Negligible (<1%); ions are free in plasma (no significant protein binding).
Calcium: ~40-50% bound to albumin; magnesium: ~25-30% bound to albumin. Binding decreases in hypoalbuminemia.
0.4 L/kg; distributes mainly in extracellular fluid (ECF).
Calcium: 0.25-0.4 L/kg; magnesium: 0.5-0.7 L/kg. Indicates distribution into extracellular fluid and bone (calcium) or intracellular and bone (magnesium).
100% (intravenous); not absorbed orally.
Intravenous: 100%. Intraperitoneal: ~70-80% (dependent on dwell time and concentration). Oral: ~30-40% for calcium and ~40-60% for magnesium (varies with formulation and GI factors).
Contraindicated in oliguric or anuric renal failure; in GFR <30 m L/min, avoid use or monitor electrolytes closely; no specific GFR-based dose adjustment.
For GFR 30-60 m L/min: reduce amino acid dose to 0.8 g/kg/day. For GFR <30 m L/min: reduce to 0.6 g/kg/day. Lipids may require adjustment based on triglyceride levels. Avoid in severe renal failure unless on dialysis.
No specific Child-Pugh based adjustments; use with caution in hepatic impairment due to risk of fluid overload.
Child-Pugh A: no adjustment. Child-Pugh B: reduce amino acids to 1.0 g/kg/day. Child-Pugh C: avoid use or reduce to 0.5 g/kg/day with close monitoring for encephalopathy. Lipids may be given at standard doses but monitor triglycerides.
Weight-based dosing: 5-10 m L/kg intravenous infusion over 1-2 hours, not to exceed 30 m L/kg/day.
Neonates and infants: amino acids 2.0-3.0 g/kg/day, lipids 1.0-3.0 g/kg/day. Children 1-10 years: amino acids 1.5-2.5 g/kg/day, lipids 1.0-2.0 g/kg/day. Administer via continuous infusion over 24 hours. Monitor serum triglycerides, bilirubin, and liver function.
Use with caution due to increased risk of fluid overload and electrolyte imbalance; adjust rate and volume based on renal function and comorbidities, typical initial dose 500 m L over 2-3 hours.
Use caution; start at low end of adult dosing (amino acids 1.2 g/kg/day, lipids 1.0 g/kg/day). Monitor renal function (creatinine clearance) and fluid status due to increased risk of fluid overload. No specific dose adjustments except based on renal function.
None.
Not for intravenous use. Peritoneal dialysis should be performed under strict aseptic technique to prevent peritonitis. Use only in patients with intact peritoneal membrane and no contraindications to peritoneal dialysis.
Use with caution in patients with severe renal impairment, heart failure, or conditions associated with sodium retention,Monitor serum electrolytes, fluid balance, and acid-base status during prolonged administration,Risk of volume overload in patients with compromised cardiac or renal function,Contains aluminum; may be toxic with prolonged use in patients with renal impairment
Monitor serum electrolytes, glucose, and acid-base status frequently. Risk of hyperglycemia, hypernatremia, hypokalemia, hypocalcemia, and metabolic alkalosis. Peritonitis and catheter-related infections are major complications. Avoid in patients with severe lactic acidosis or hypokalemia. Use caution in patients with glucose intolerance or liver disease.
Hypersensitivity to any component,Severe hypernatremia or severe hyperchloremia,Severe metabolic alkalosis,Patients with contraindications to intravenous fluid administration
Absolute: Hypersensitivity to any component, pre-existing severe metabolic alkalosis, documented non-functioning peritoneal membrane, or conditions compromising peritoneal integrity (e.g., extensive adhesions, diaphragmatic defects). Relative: Uncontrolled hyperglycemia, severe hypokalemia, or recent abdominal surgery.
No food interactions are relevant as Physiosol p H 7.4 is not ingested. It is used exclusively for topical irrigation during medical procedures.
No specific food interactions. However, patients should maintain a diet appropriate for chronic kidney disease on peritoneal dialysis, including controlled intake of potassium, phosphorus, and fluids as directed by their healthcare provider.
Physiosol p H 7.4 (balanced electrolyte solution) is considered low risk for teratogenicity. There are no known fetal risks associated with its use in any trimester, as it is a physiological solution. However, large volumes or rapid administration could theoretically cause maternal electrolyte imbalances, which may indirectly affect the fetus.
Limited data; no evidence of teratogenicity in animal studies; avoid if possible in first trimester due to theoretical risks of uremic toxin accumulation.
Physiosol p H 7.4 is compatible with breastfeeding. No M/P ratio is available; however, components are normal plasma constituents and unlikely to be excreted into breast milk in clinically significant amounts.
Excreted into breast milk in low amounts; M/P ratio not established; compatible with breastfeeding with monitoring of infant electrolytes.
No specific dose adjustment is required for pregnancy. However, consider increased plasma volume and glomerular filtration rate in pregnancy; standard dosing is appropriate, but monitor for volume overload.
Increased plasma volume in pregnancy may require dose adjustments; monitor serum potassium and calcium; hemofiltration dose may need increased frequency or volume.
Physiosol p H 7.4 is a balanced crystalloid solution used for irrigation, not for systemic administration. In the operating room, it is preferred for peritoneal lavage due to its neutral p H, which minimizes tissue irritation. Do not use for intravenous infusion; verify labeling to avoid confusion with IV solutions. Warm to body temperature before use to prevent hypothermia during large-volume irrigation.
PHOXILLUM BK 4/2.5 is a peritoneal dialysis solution containing 4% icodextrin and 2.5% amino acids. It is used for one exchange per day in continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD). Avoid use in patients with known hypersensitivity to icodextrin or amino acids. Monitor serum osmolality and glucose levels, as icodextrin may interfere with glucose oxidase-based glucometers, leading to falsely elevated readings. Use with caution in patients with liver disease due to potential amino acid accumulation.
This solution is used to rinse body cavities during surgery, not for intravenous use.,You may feel a cooling sensation during irrigation; this is normal.,Report any signs of infection at the surgical site, such as redness, swelling, or discharge.,Do not attempt to use this solution at home; it is for hospital use only.
Use only one bag per day, typically for the long dwell (overnight).,Do not use if the solution is cloudy or the bag is damaged.,Store at room temperature, away from direct sunlight.,Monitor for signs of infection like redness, swelling, or drainage at the catheter site.,Report any unusual abdominal pain or cloudy effluent immediately.,If using a glucose meter, ensure it is not affected by icodextrin; consider using a glucose dehydrogenase-based meter.,Maintain a balanced diet as amino acids may affect protein intake needs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER vs PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, answered by our medical review team.
PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER is a Irrigation Solution that works by Replacement of extracellular fluid and electrolytes; provides buffering capacity via bicarbonate precursor (acetate) and maintains physiological p H.. PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is a Irrigation Solution that works by The drug is a bicarbonate-based peritoneal dialysis solution that buffers metabolic acidosis, removes uremic toxins, and corrects electrolyte imbalances via diffusion and ultrafiltration across the peritoneal membrane. It does not have a traditional receptor-mediated mechanism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER and PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Irrigation Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER is: Intravenous infusion, rate adjusted based on clinical status and electrolyte needs; typical adult dose is 500-1000 m L over 1-2 hours.. The standard adult dose of PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is: Intravenous infusion only. Each 1000 m L bag contains 4 g of amino acids and 2.5 g of lipids. Typical adult dose: 1.5-2.0 g/kg/day of amino acids (equivalent to 37.5-50 m L/kg/day) and 1.0-1.5 g/kg/day of lipids. Administer at a rate not to exceed 0.11 g/kg/hour of amino acids and 0.15 g/kg/hour of lipids. For a 70 kg patient, this equals approximately 2.6-3.5 L/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER and PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER is classified as Category C. Physiosol pH 7.4 (balanced electrolyte solution) is considered low risk for teratogenicity. There are no known fetal risks associated with its use in any trimester, as it is a phys. PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is classified as Category C. Limited data; no evidence of teratogenicity in animal studies; avoid if possible in first trimester due to theoretical risks of uremic toxin accumulation.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.